ISTA Vitrase Clears FDA; Full Launch Awaits New Vial Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will begin providing samples by July; reimbursement issues are expected to be resolved within three to six months. The approval of hyaluronidase removes the product from the drug shortages list.